cell transplantation

[Jasper Therapeutics, Inc. (Business Wire, Inc.)] Jasper Therapeutics, Inc. announced the initiation of a Phase I/II clinical trial to evaluate JSP191, the company’s anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning regimen prior to allogeneic transplant for chronic granulomatous disease.

[Journal of Clinical Oncology] This phase Ib/II study evaluated the safety and efficacy of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin combined with the B-cell lymphoma-2 inhibitor venetoclax in newly diagnosed patients with acute myeloid leukemia (AML) and relapsed or refractory AML.

[Bone Marrow Transplantation] Researchers performed a retrospective, registry-based analysis to elucidate the prognostic value of runt-related transcription factor 1 (RUNX1) mutation after allogeneic stem cell transplantation for AML patients.

[Bone Marrow Transplantation] Investigators reported 236 adult patients who received haploidentical HSC transplantation with post-transplant cyclophosphamide.

[British Journal of Dermatology] The authors discuss the various forms of cell therapy currently available, their utility in the management of immune-mediated inflammatory diseases (IMIDs) and emerging evidence for efficacy in severe psoriasis unresponsive to biologic therapy.

[NPJ Regenerative Medicine] Researchers analyzed the oxidative damage in models of liver injury characterized by biliary epithelial cells/hepatic progenitor cells (HPCs) activation and defined the impact of redox balance perturbation on HPC fate. They then identified Nuclear factor (erythroid-derived 2)-like 2 as the main transcription factor involved in the activation of HPCs.